B+
Bull case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
TBPH
Theravance BiopharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings bull case is that Q1 results reinforced the non-pipeline value floor: quarter-end cash was about $395 million with no debt, Q1 net loss narrowed materially year over year to $4.9 million from $13.6 million, YUPELRI trends stayed positive, and management reiterated confidence in the 2026 TRELEGY milestone path [#8-K-2026-05-07] [#10-Q-2026-05-07].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.9.
What can break
Management's $60-$70 million annualized cash-flow goal depends on delivering the planned restructuring and sustaining lower operating expenses into Q3 2026 and beyond [#8-K-2026-05-07].
Momentum
27
Value
63
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $22.00 · Bear $13.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum27 · Δ7d +9.0
Value63 · Δ7d -0.0
Sentiment63 · Δ7d +5.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.9.
Contradictions & invalidation
- • Management's $60-$70 million annualized cash-flow goal depends on delivering the planned restructuring and sustaining lower operating expenses into Q3 2026 and beyond [#8-K-2026-05-07].
- • TBPH is increasingly dependent on YUPELRI commercial durability after winding down ampreloxetine, which raises concentration risk even after the Hatch-Waxman litigation overhang was resolved [#8-K-2026-05-07] [#10-K-2026-03-23].
- • The bear case is that the earnings release did not change the core limitation created by the March 2026 CYPRESS failure: TBPH is now a thinner-growth commercial cash-flow story with a strategic review that may produce no deal, while much of the valuation support depends on executing the restructuring and preserving YUPELRI/TRELEGY economics.
Catalyst clock
2026-08-06
Q3 2026 cost-reset proof point after Q1 earnings update
Lead driver: Sentiment · See AI snapshot
Momentum
27
9% active weight
Current posture
7d trendImproving
Δ7d
+9.0
Δ21d
-5.7
Value
63
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+6.2
Sentiment
63
62% active weight
Current posture
7d trendImproving
Δ7d
+5.9
Δ21d
+1.2
Why this grade
Composite grade C. Momentum 27.3 / Value 62.9 / Sentiment 63.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$878.47M
Beta
0.15
Shares Out
51.92M
P/E (TTM)
32.7
P/S (TTM)
11.62
P/FCF (TTM)
3.83
Rev YoY
-20.9%
EPS YoY
-110.6%
Gross Margin
+94.4%
Op Margin
+2.1%
Net Debt
-$239.86M
Current Ratio
13.54
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data